



Published in final edited form as:

Nat Commun. ; 6: 8282. doi:10.1038/ncomms9282.

## Role of T cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss

Ighovwerha Ofotokun<sup>1,\*</sup>, Kehmia Titanji<sup>2,#</sup>, Tatyana Vikulina<sup>2,#</sup>, Susanne Roser-Page<sup>3,#</sup>, Masayoshi Yamaguchi<sup>2</sup>, Majd Zayzafoon<sup>4</sup>, Ifor R. Williams<sup>5</sup>, and M. Neale Weitzmann<sup>2,3,\*</sup>

<sup>1</sup>Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA USA and Grady Healthcare System, Atlanta, GA, USA

<sup>2</sup> Division of Endocrinology & Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA USA

<sup>3</sup>Atlanta Department of Veterans Affairs Medical Center, Decatur, GA USA

<sup>4</sup>Department of Pathology, University of Alabama at Birmingham, Birmingham, AL USA

<sup>5</sup>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA USA

### Abstract

HIV infection causes bone loss. We previously reported that immunosuppression-mediated B-cell production of receptor activator of NF- $\kappa$ B ligand (RANKL) coupled with decline in osteoprotegerin correlate with decreased bone mineral density (BMD) in untreated HIV-infection. Paradoxically, antiretroviral therapy (ART) worsens bone loss although existing data suggest that such loss is largely independent of specific antiretroviral regimen. This led us to hypothesize that skeletal deterioration following HIV disease reversal with ART may be related to T-cell repopulation and/or immune-reconstitution. Here we transplant T cells into immunocompromised mice to mimic ART-induced T-cell expansion. T-cell reconstitution elicits RANKL and TNF $\alpha$  production by B-cells and/or T-cells, accompanied by enhanced bone resorption and BMD loss. Reconstitution of TNF $\alpha$ - or RANKL-null T-cells and pharmacological TNF $\alpha$  antagonist all protect cortical, but not trabecular bone, revealing complex effects of T-cell-reconstitution on bone turnover. These findings suggest T-cell repopulation and/or immune-reconstitution as putative mechanisms for bone loss following ART initiation.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

**Address Correspondence to:** M. Neale Weitzmann, Division of Endocrinology & Metabolism & Lipids, Emory University School of Medicine, 101 Woodruff Circle, 1305 WMRB, Georgia 30322-0001. Tel: (404) 727-1389; Fax: (404) 727-1300; mweitzm@emory.edu. Ighovwerha Ofotokun, Infectious Diseases, Emory University School of Medicine, 49 Jesse Hill Jr Drive, Atlanta, GA 30303; Tel: (404) 616-0659; Fax: (404) 616 0592; iofotok@emory.edu.

\*These authors jointly supervised this work.

#These authors contributed equally to this work.

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Authorship contributions:** M. Neale Weitzmann and Ighovwerha Ofotokun designed the studies, analyzed the data, and wrote the manuscript. Kehmia Titanji, Tatyana Vikulina, Susanne Roser-Page, Masayoshi Yamaguchi and Majd Zayzafoon performed the studies. Ifor R. Williams provided critical reagents necessary to undertake the studies. The contents of this manuscript do not represent the views of the Department of Veterans Affairs, the National Institutes of Health or the United States Government.

## Keywords

Osteoporosis; antiretroviral therapy; ART; osteoclasts; bone loss; T cell; HIV; adoptive transfer

---

## INTRODUCTION

HIV infection is associated with skeletal deterioration<sup>1-6</sup>. Nearly two thirds of HIV-infected patients exhibit osteopenia, with osteoporosis occurring in up to 15% of HIV-infected subjects<sup>7-9</sup>. Consequently, an overall 2-4 fold higher prevalence of bone fracture and up to 9 fold increase in hip fracture is reported for HIV-infected patients compared to the general population<sup>10-15</sup>. Using an HIV transgenic rat model, we demonstrated that HIV-induced bone loss is related to altered B cell function<sup>16</sup> presumably via loss of co-stimulation, a consequence of CD4<sup>+</sup> T cell lymphopenia. We recently validated these animal studies in humans, demonstrating a significant increase in B cell production of the key osteoclastogenic factor, receptor activator of NF- $\kappa$ B ligand (RANKL) and a simultaneous decline in its decoy receptor and physiological antagonist, osteoprotegerin (OPG). The B cell RANKL/OPG ratio was significantly correlated with bone mineral density (BMD) at the femoral neck and total hip in HIV-infected subjects, suggesting an immunocentric basis for bone loss in HIV-infection<sup>17</sup>. Furthermore, studies of T cells in HIV infected subjects suggest a heightened state of activation that likely further contributes to HIV-induced bone loss<sup>18</sup>.

Antiretroviral therapy (ART) causes paradoxical worsening of skeletal health<sup>1-3,19-21</sup>. A decline in BMD of up to 6% is observed with ART initiation, a loss comparable to that sustained during the early phase of menopause<sup>19</sup>. Previous attempts to identify the mechanisms of ART-induced bone loss separately from those of HIV itself have been futile, as the direct actions of ART on bone cells *in vitro*<sup>22-24</sup> and in animal models *in vivo*<sup>25</sup> frequently fail to recapitulate ART-effects observed in HIV-infected patients. Nevertheless, ART drug classes with distinct modes of action mediated through different biochemical pathways are all associated with bone loss<sup>26-28</sup> suggesting that bone loss is independent of antiretroviral regimen<sup>26,29</sup> and implying an indirect effect of ART on bone homeostasis. One such indirect action may be related to HIV disease reversal and homeostatic expansion of the immune cells. In fact, in other non-HIV pathologic conditions such as periodontal disease and postmenopausal osteoporosis, immune activation and inflammation, processes seen during CD4<sup>+</sup> T cell repopulation and expansion with ART, are involved in the pathogenesis of bone loss<sup>30-34</sup>.

Because of the universality of this bone loss to all ART drug classes, and the known impact of immune activation on bone catabolism in other disease states, an immunocentric explanation for ART-induced bone loss is likely, although has not previously demonstrated. We thus hypothesized that T cell repopulation and immune reactivation, a consequence of ART-induced HIV disease reversal, may explain the enhanced bone loss following ART initiation. We tested this hypothesis by simulating immune reconstitution in the context of immunodeficiency using T cell deficient TCR $\beta$  knockout (KO) mice that we reconstituted by adoptive transfer of syngeneic T cells. We show that as with ART-induced T cell

repopulation, a significant increase in bone resorption and a corresponding decline in BMD and cortical and trabecular bone structure follows T cell reconstitution. Transferred T cells produced significant concentrations of RANKL and TNF $\alpha$ . Furthermore, reconstitution of TNF $\alpha$ - or RANKL-null T cells, as well as treatment with the pharmacological TNF $\alpha$  antagonist Etanercept, led to significant protection of cortical bone, but interestingly, not of trabecular bone. Our data support a role for T cell reconstitution as a key mechanism of bone loss. We further demonstrated that bone loss associated with disruption of the immuno-skeletal interface could be fully prevented by anti-resorptive medication prophylaxis using zoledronic acid in T cell reconstituted animals.

## RESULTS

### Loss of BMD following T cell reconstitution

To investigate whether T cell repopulation and/or immune reconstitution independently cause bone resorption in the absence of HIV infection or AIDS sequelae, we transplanted CD3<sup>+</sup> T cells into genetically identical syngeneic T cell deficient TCR $\beta$  knockout (KO) mice by adoptive transfer.

T cell-deficient TCR $\beta$  KO mice on a C57BL6 background were injected with vehicle (sham) or reconstituted by adoptive transfer of  $1 \times 10^5$  immunomagnetically purified CD3<sup>+</sup> T cells (both CD4<sup>+</sup> and CD8<sup>+</sup> at physiological ratios). Purified T cells were verified as 97% CD3<sup>+</sup> by flow cytometry (Supplementary Fig. 1A). T cell number and proliferation were quantitated by flow cytometry 12 weeks later. As expected, T cells had significantly reconstituted in the spleen and bone marrow (BM) after adoptive transfer (Supplementary Fig. 1B).

Following reconstitution of the TCR $\beta$  KO mice, we quantitated BMD using *in vivo* bone densitometry (dual energy X-ray absorptiometry [DXA]). Over a 12-week period, we observed a dramatic progressive decline in accrual of total body, lumbar spine, femur, and tibia BMD in reconstituted mice compared to non-transplanted (sham) TCR $\beta$  KO mice (Fig. 1A-D), supporting the hypothesis that T cell repopulation can initiate conditions propitious for bone loss.

### Loss of cortical and trabecular bone following T cell reconstitution

Trabecular and cortical bone structure were independently quantified in femurs from sham and reconstituted mice 12 weeks after T cell adoptive transfer, using high-resolution (6  $\mu$ m) micro-computed tomography ( $\mu$ CT). Representative  $\mu$ CT reconstructions of sham and CD3<sup>+</sup> T cell reconstituted TCR $\beta$  KO femurs (Fig. 1E) showed severe deterioration of both trabecular and cortical bone structure. Severely denuded trabecular structure in the femoral epiphysis and metaphysis was also evident on Masson's Trichrome-stained histological sections (Fig. 1F).

Quantitative micro-architectural indices of trabecular and cortical structure were further computed from  $\mu$ CT slices (Table 1). Tissue volume (TV), a reflection of bone size, was not significantly altered, however trabecular bone volume (BV) was drastically reduced in CD3<sup>+</sup> T cell reconstituted mice, leading to diminished bone volume fraction (BV/TV), a key index

of trabecular bone mass. Trabecular microarchitecture revealed diminished thickness (Tb. Th.) and number (Tb. N.), and increased trabecular separation (Tb. Sp.) with an overall significant decline in volumetric BMD (TV. D.). T cell reconstitution was also associated with degradation of cortical bone structure, with significant decline in both cortical area (Ct. Ar.) and thickness (Ct. Th.) two key indices of cortical bone mass.

### **Biochemical indices of bone turnover, osteoclastogenic cytokines and osteoclastogenesis following T cell reconstitution**

Serum biochemical markers of bone turnover were quantitated in sham- and T cell-reconstituted TCR $\beta$  KO mice 12 weeks after T cell reconstitution. Bone resorption measured by serum C-terminal telopeptide of type I collagen (CTX) was significantly elevated in T cell reconstituted mice (Fig. 1G), while bone formation (measured by serum osteocalcin) was modestly, but significantly suppressed (Fig. 1H), consistent with rapid bone loss observed in this model. Serum RANKL, the key osteoclastogenic cytokine (Fig. 1I), and its amplifier TNF $\alpha$  (Fig. 1K) were significantly elevated in T cell reconstituted mice at 12 weeks. Although there was some variability in individual animal responses, overall the RANKL antagonist OPG was not significantly different (Fig. 1J) likely leading to an overall increase in the RANKL/OPG ratio, conditions favorable for bone loss. Bone marrow from reconstituted mice cultured *ex vivo* in the absence of exogenous RANKL generated significantly higher numbers of osteoclasts than bone marrow from sham mice (Fig. 1L), suggesting a more osteoclastogenic bone marrow microenvironment.

### **Decline in bone formation following T cell reconstitution**

To confirm at the tissue level the decline in bone formation following adoptive transfer we performed quantitative histomorphometry of mouse femurs (Table 1). The number of osteoblasts per bone surface (N. Ob/BS), mineral apposition rate (MAR) and bone formation rate (BFR/TV) were all significantly diminished. BFR normalized for bone surface (BS) showed a strong negative trend but fell short of statistical significance, likely due to significantly diminished bone surfaces in the transplanted mice. BFR/TV is the index that correlates most closely with bone turnover markers such as osteocalcin<sup>35</sup>.

### **T cell RANKL is significantly elevated following T cell reconstitution**

To assess whether the increased RANKL observed following T cell reconstitution was from T cells or other immune cells, we used flow cytometry to evaluate RANKL expression from known major RANKL-producing populations in the spleen and/or BM. We studied T cell-reconstituted TCR $\beta$  KO mice one week after T cell transfer, a time when T cells are undergoing homeostatic expansion and are rapidly repopulating available niches. Representative dot plots of all flow cytometry studies reported below are provided in Supplementary Figures 2 to 7. The proportion of CD4<sup>+</sup> T cells producing RANKL was significantly elevated in BM (Fig. 2A) and spleen (Fig. 2B), in reconstituted TCR $\beta$  KO mice compared with WT controls. The proportion of BM CD8<sup>+</sup> T cells producing RANKL was low in both WT and reconstituted mice (Fig. 2C), but the proportion of splenic CD8<sup>+</sup> T cells producing RANKL was significantly higher in reconstituted mice (Fig. 2D).

The percentage of total (B220<sup>+</sup>) BM B lineage cells (Fig. 2E) as well as segregated B cell precursors and immature B cells (B220<sup>dim</sup>) (Fig. 2F) and mature B cells (B220<sup>bright</sup>) (Fig. 2G) producing RANKL was quantified and although most animals were modestly elevated overall the data fell short of statistical significance. Splenic RANKL production by B cells was lower than for BM overall and no changes or trends were observed in reconstituted mice (Fig. 2H).

To confirm that the increase in RANKL observed with T cell reconstitution came from immune cells rather than osteoblasts and their precursors, the bone marrow stromal cells (BMSC), populations long considered to be a rich basal source of RANKL, we assessed the proportion of RANKL-producing osteoblasts (VCAM<sup>+</sup> cells in the bone marrow) and BMSC (CD29<sup>+</sup> SCA1<sup>+</sup> cells in the bone marrow)<sup>36</sup>. Approximately 80% of osteoblasts and 40% of BMSC produced RANKL in WT mice but neither population was significantly changed by T cell reconstitution (Figures. 2I and 2J respectively). Dendritic cells were not a significant source of RANKL in WT or reconstituted BM (Fig. 2K) or spleen (Fig. 2L).

### T cell reconstitution increases TNF $\alpha$ -producing B cells and T cells

We next assessed the cellular sources of elevated TNF $\alpha$  using flow cytometry. The proportion of TNF $\alpha$ -producing BM CD4<sup>+</sup> (Fig. 2M) and CD8<sup>+</sup> (Fig. 2O) T cells and splenic CD4<sup>+</sup> (Fig. 2N) and CD8<sup>+</sup> (Fig. 2P) T cells were all significantly elevated in reconstituted mice compared with WT.

The percentage of total TNF $\alpha$  producing BM B lineage cells (Fig 2Q), B cell precursors and immature B cells (Fig. 2R), and mature BM (Fig. 2S) and splenic (Fig. 2T) B cells from T cell reconstituted mice was significantly elevated compared to cells from WT mice, but fell short of significance compared to sham reconstituted TCR $\beta$  KO mice.

TNF $\alpha$ -producing BM and splenic monocytes/macrophages (CD11b<sup>+</sup>) (Supplementary Figures 7A and 7B respectively) were also significantly increased in reconstituted mice relative to WT mice, but despite a strong trend fell short of significance relative to TCR $\beta$  KO controls.

### TNF $\alpha$ - or RANKL-KO T cell reconstitution prevents cortical but not trabecular, bone loss

To test the direct contributions of T cell RANKL and TNF $\alpha$  production to bone loss we reconstituted  $1 \times 10^5$  CD3<sup>+</sup> T cells from either TNF $\alpha$  KO mice or RANKL KO mice into TCR $\beta$  KO mice. BMD was quantified at baseline and at 12 weeks after transplant. Reconstitution of TNF $\alpha$  KO or RANKL KO T cells led to partial protection from bone loss compared to WT T cells at total body (Fig. 3A), and significant protection of the femurs (Fig. 3B) and lumbar spine (Fig. 3C). Representative 3D reconstructions of isolated femurs by  $\mu$ CT (Fig. 3D) and quantitative analysis of femoral microarchitecture in Table 2 revealed significant protection from cortical bone loss (both Ct. Ar. and Ct. Th.). RANKL KO T cells showed virtually complete protection, while TNF $\alpha$  KO T cells caused a significantly bunted, bone loss. By contrast, both TNF $\alpha$  and RANKL KO T cells elicited significant trabecular bone loss, with BV/TV indistinguishable from WT T cells and most indices of bone microarchitecture comparable to that of WT T cells.

The bone resorption marker CTx (Fig. 3E) was significantly increased in the WT T cell transplanted group but not in TNF $\alpha$  or RANKL KO groups, although the median values were comparable to that of mice receiving WT T cells, suggesting an overall increased rate of resorption that likely accounts for the trabecular bone loss.

Osteocalcin revealed a significant decline in bone formation in WT transplanted T cells and remained significantly depressed in the TNF $\alpha$  and RANKL null T cell transplanted groups (Fig. 3F).

Serum RANKL (Fig. 3G) was increased by transfer of WT T cells and remained elevated in TNF $\alpha$  null T cell transplant but was not significantly elevated in mice reconstituted with RANKL KO T cells, suggesting that T cells are the major source of RANKL driving bone loss during reconstitution. OPG was not significantly elevated by WT or RANKL KO T cell transplant but interestingly was significantly increased by transfer of TNF $\alpha$  KO T cells (Fig. 3H).

As TNF $\alpha$  null T cells did not diminish RANKL concentrations the data suggest that the mode of action of TNF $\alpha$  in this model is likely to amplify RANKL activity rather than to promote its production.

TNF $\alpha$  production (Fig. 3I) was significantly increased by WT, TNF $\alpha$  KO and RANKL KO T cells, suggesting that T cells alone do not account for all the TNF $\alpha$  produced, and consistent with our flow analyses. In addition, some mice in this group had unusually high TNF $\alpha$  levels, suggesting that loss of T cell TNF $\alpha$  may promote a compensatory production from other sources.

Taken together, these data suggest that production of TNF $\alpha$  and RANKL by T cells contributes significantly to direct cortical bone loss. Interestingly, T cell production of either TNF $\alpha$  or RANKL was dispensable for trabecular bone loss, possibly due to involvement of other immune cells such as B cells as observed by flow cytometry in Fig. 2.

### **TNF $\alpha$ ablation blocks cortical but not trabecular, bone loss**

To assess the significance of global TNF $\alpha$  production in T cell reconstitution bone loss, mice were treated with the pharmacological TNF $\alpha$  antagonist Etanercept. TCR $\beta$  KO mice were injected with vehicle (sham) or reconstituted by adoptive transfer of  $1 \times 10^5$  CD3 $^+$  T cells, with or without Etanercept (3 mg/Kg, 3 times per week).

Prospective BMD quantification over 12 weeks revealed significant bone loss following T cell reconstitution in the vehicle injected group, but significant protection from bone loss in Etanercept-treated groups at the total body (Fig. 4A) and femurs (Fig. 4C) with partial protection at tibias (Fig. 4D). By contrast, the axial skeleton (lumbar spine), a trabecular-rich site, was not significantly protected by Etanercept (Fig. 4B), again suggesting a more pronounced effect of TNF $\alpha$  on cortical than trabecular bone mass. This was verified in the femur by quantifying separate cortical and trabecular microarchitecture by  $\mu$ CT.

Representative 3D reconstructions are shown in Fig. 4E with quantitative analysis in Table 3. As observed for TNF $\alpha$  KO T cell reconstitution, the TNF $\alpha$  antagonist significantly protected cortical bone thickness and area. Trabecular bone indices including BV/TV

revealed partial protection with Etanercept but were not significantly different from either sham or T cell reconstituted mice.

Etanercept was further associated with a partial but significant decrease in serum CTx compared to T cell reconstituted groups (Fig. 4F). By contrast, serum RANKL was not affected by TNF $\alpha$  neutralization (Fig. 4G), suggesting that the mode of action of TNF $\alpha$  in this model is likely to amplify RANKL activity rather than promote its production. OPG was also modestly but significantly increased by T cell transplantation in this experiment and was partially but not significantly reduced by TNF $\alpha$  suppression (Fig. 4H).

As expected, T cell adoptive transfer caused a significant increase in TNF $\alpha$  (Fig. 4I), however due to Etanercept cross-reactivity with the ELISA, we were unable to quantify changes in TNF $\alpha$  production in Etanercept-treated mice.

Taken together, these data suggest that TNF $\alpha$  produced by T cells is a significant inducer of cortical bone loss.

### **T cell number impacts the magnitude of reconstitution bone loss**

It has been reported that patients with low baseline CD4 count undergo greater bone loss after initiating ART<sup>37</sup>. To determine whether the number of starting T cells affects the extent of bone loss, we adoptively transferred different numbers of CD3<sup>+</sup> T cells into TCR $\beta$  KO mice and quantified bone turnover and structure after 3 months. Adoptive transfer of a low number ( $1 \times 10^3$ ) of T cells produced no significant loss of BMD as quantified by DXA in the lumbar spine (Fig. 5A) or femur (Fig. 5B), while transfer of a very large number ( $1 \times 10^7$ ) produced a small but non-significant loss of BMD in the spine but not femur, compared to  $1 \times 10^5$  T cells that produced significant bone loss at both spine and femur.  $\mu$ CT analysis however, revealed that high concentrations of T cells produced significant loss of trabecular bone structure, but not of cortical bone (as was reflected by DXA a technique sensitive to cortical but not trabecular bone changes), while the low dose of T cells ( $1 \times 10^3$ ) had no significant effect on either compartment (Fig. 5C and Table IV).

Overall, serum CTx was only significantly higher with  $1 \times 10^5$  T cells (Fig. 5D) although there was significant variability between individual animals in all transplanted groups. Osteocalcin (Fig. 5E) was slightly suppressed relative to sham irrespective of T cell number although all groups fell short of significance. Serum RANKL (Fig. 5F) was significantly increased in both the high ( $1 \times 10^7$ ) and moderate ( $1 \times 10^5$ ) group, but not the low number of transplanted T cells ( $1 \times 10^3$ ).

By contrast, serum TNF $\alpha$  concentrations were significantly elevated in moderate ( $1 \times 10^5$ ) and low ( $1 \times 10^3$ ) groups.

Taken together the data suggest that an increase in RANKL alone is sufficient for trabecular bone loss to occur but TNF $\alpha$  and RANKL are needed for cortical bone loss. This interpretation is consistent with the known action of TNF $\alpha$  on bone, which is to indirectly amplify RANKL-induced osteoclastogenesis and bone resorption, not to promote osteoclastogenesis directly<sup>38-40</sup>.

### Antiresorptive therapy reverses T cell reconstitution bone loss

In our final study, as a “proof of concept” that bone loss associated with T cell reconstitution can be blocked pharmacologically without impairing T cell reconstitution, CD3<sup>+</sup> T cell reconstituted mice were injected once with zoledronic acid (a long-acting antiresorptive drug approved for amelioration of postmenopausal osteoporosis<sup>41</sup>) at the time of adoptive transfer and BMD was quantitated by DXA at baseline and at 12 weeks. While T cell reconstituted mice lost total body BMD (Supplementary Fig. 8A) including at the lumbar spine (Supplementary Fig. 8B), femur (Supplementary Fig. 8C) and tibia (Supplementary Fig. 8D), the zoledronic acid-treated group was protected from bone loss at all sites and actually gained BMD relative to the sham group during follow-up (Supplementary Fig. 8A-D). Serum CTx was significantly decreased with zoledronic acid treatment (Supplementary Fig. 8E) while osteocalcin remained unchanged (Supplementary Fig. 8F). Importantly, at 4 weeks, the proportion of T cells in the peripheral circulation were not significantly different between vehicle and zoledronic acid-treated mice (14.8% ± 0.2 vs. 13.7% ± 4.0 respectively, N=8 sham and 5 CD3<sup>+</sup> T cell/group), suggesting that zoledronic acid does not impede T cell reconstitution.

## DISCUSSION

Although HIV- and ART-induced bone loss has long been recognized, the underlying pathophysiology remains poorly understood. Emerging data suggest that direct HIV effects on the skeleton may be linked to altered immune function including activation of T cells<sup>18</sup> and significant B cell dysfunction, with consequent increase in the RANKL/OPG ratio, favoring enhanced bone catabolism and loss of BMD<sup>16,17</sup>. Immune effects of ART in patients are however complex and while some studies suggest that ART may diminish immune activation at least in the short term<sup>42-44</sup> other studies suggest that reversal of inflammation by ART is incomplete and that inflammation persists, albeit at a lower level indefinitely<sup>45</sup>.

We now provide a “proof of concept” that like HIV-infection itself, the bone effect of ART may too have an immunocentric component driving bone loss though a mechanism aligned with immunologic events associated with HIV disease reversal and immune reconstitution and/or reactivation, that may lead to persistent low-level chronic inflammation.

It is well established that the immune and skeletal systems are intricately linked via a centralization of common cell types and cytokine mediators – the “immune-skeletal interface”<sup>16,34,46</sup>. In HIV-infected patients, suppression of HIV replication with ART leads to a partial recovery of depleted CD4<sup>+</sup> T cells through mechanisms involving both peripheral expansion of existing T cell pools and IL-7-mediated thymic reactivation pathways<sup>47,48</sup>. Furthermore, CD4<sup>+</sup> T cells are central regulators of adaptive immunity and potently affect the action of other immune cells, including professional antigen presenting cells (APCs) such as dendritic cells, macrophages and B cells, all of which are capable of secreting TNF $\alpha$  and/or RANKL. In this study we investigated whether activation of the expanding T cell pool, together with the reactivation of humoral immunity and antigen presentation to APCs associated with ART-induced disease reversal can lead to constitutive



production of key osteoclastogenic cytokines including TNF $\alpha$  and RANKL, tilting the RANKL/OPG ratio in favor of enhanced bone breakdown.

To establish a mechanistic basis for immune reconstitution-induced bone loss, we adoptively transferred T cells into an animal model of T cell immunodeficiency (TCR $\beta$  KO mice) to simulate T cell repopulation, as is likely to occur following ART-initiation in HIV-infected patients. We observed a dramatic decline in BMD at all anatomic sites examined following adoptive transfer of a modest number ( $1 \times 10^5$ ) of CD3 $^+$  T cells supporting the hypothesis that T cell repopulation can independently induce bone loss in the absence of HIV-infection, AIDS pathologies, and other confounding risk factors for osteoporosis that coexist in human populations.

Consistent with elevated serum RANKL and TNF $\alpha$  our flow cytometry data suggest that reconstituting T cells are significant sources of RANKL and TNF $\alpha$ . Although CD4 $^+$  T cells are severely depleted by HIV infection, significant losses in CD8 $^+$  T cell populations also occur in advanced HIV infection and recover following ART<sup>49</sup>. To maintain this dynamic we initially repleted T cell-deficient mice with both CD8 $^+$  and CD4 $^+$  T cells in normal physiological ratios (CD3 $^+$ ). However, our data revealed that reconstituted CD8 $^+$  T cells are also a significant source of RANKL (Fig. 2D) and TNF $\alpha$  (Figure 2O and 2P).

As RANKL and TNF $\alpha$  production is associated with T cell activation we performed flow cytometry analysis of T cells three months after reconstitution and found the majority of transplanted CD4 $^+$  and CD8 $^+$  T cells still express the activation marker CD69, and KI-67 a marker of proliferation and synonymous with T cell activation (Supplementary Figure 9). These data provide additional support to our hypothesis of long term bone loss associate with chronic T cell activation.

Furthermore, our data also support a contribution by B cells and monocytes/macrophages, where modest increases were observed. Given the relatively large number of B cell populations in the bone marrow (25% of nucleated cells) even small increases in RANKL and/or TNF $\alpha$  production may add up to a significant overall contribution to total cytokine levels. Both B cells and macrophages also serve as APCs that normally interact with T cells as part of adaptive immune function. Our data thus suggest that bone loss occurs as a result of a generalized reactivation of the adaptive immune complex as a whole following reconstitution of the T cells. This model is outlined diagrammatically in Figure 6.

It has been reported that patients with low baseline CD4 count have greater bone loss following ART initiation<sup>37</sup>, suggesting that the extent of homeostatic repopulation may have an impact on bone turnover. Interestingly, the number of T cells reconstituted did indeed have a significant and complex effect on bone loss as a modest number of starting T cells elicited severe bone loss in contrast to very low and very high numbers. Furthermore, very high numbers of T cells induced severe trabecular, but not cortical bone loss, while modest T cell numbers caused loss in both compartments. Very low numbers of T cells did not induce significant bone loss consistent with a failure to upregulate RANKL production. Interestingly, TNF $\alpha$  production was significantly elevated in this group, but was insufficient to promote bone loss in the absence of increase RANKL. These data are consistent with the

action of TNF $\alpha$ , which is not directly osteoclastogenic but functions to synergistically amplify the activity of RANKL<sup>38-40</sup>. Another interesting observation is that very high concentrations of transferred T cells produced RANKL production but not TNF $\alpha$  and led to trabecular, but not cortical, bone loss. The amplificatory role of TNF $\alpha$  thus appears to be essential to amplify RANKL to induce a robust cortical bone loss. Indeed transplantation of T cells deficient in TNF $\alpha$  production likewise led to only trabecular bone loss. These data are further consistent with the fact that pharmacological ablation of TNF $\alpha$  using Etanercept also significantly protected cortical bone while mediating only weak protection of trabecular bone mass.

The transplantation of T cells deficient in RANKL production led to complete protection of cortical bone, however surprisingly did not provide significant protection from trabecular bone loss. These data suggest that additional sources of RANKL such as those from B cells may be sufficient to promote trabecular bone loss in the presence of permissive concentrations of TNF $\alpha$ .

The reason that different concentrations of T cells lead to somewhat different cytokine production and bone loss is not presently clear, however we speculate that higher doses of T cells may lead to reconstitution too rapidly to generate sufficient prolonged TNF $\alpha$  production, while too few T cells may produce inadequate concentrations of RANKL to effectively drive bone loss.

Another plausible explanation is that the expansion of T cells from a modest pool may lead to a contraction of the T cell repertoire and accumulation of a relatively large number of T cell clones responding robustly to foreign and self-antigens. Although rare, such reactive T cell clones would likely have a selective advantage and more effectively reconstitute than non-reactive clones, leading to their preferential amplification. High concentrations of reactive T cell populations could mediate a persistent inflammatory response. Persistent inflammation is indeed a well-documented feature of patients on long term ART<sup>45,50</sup> and although the cause is unclear, our mouse model may indeed be replicating this event. A similar effect is observed in aging (inflammaging) due to age-associated contraction of the T cell repertoire leading to accumulation of autoreactive T cells<sup>51</sup> and bone loss. This explanation is consistent with our observations of chronic bone loss persisting for at least 3 months in mice, time points well beyond the 2-3 week time frame normally required for homeostatic expansion to be completed following adoptive transfer.

The fact that not only T cells produce RANKL and/or TNF $\alpha$ , but also multiple other immune cells including APCs, B cells and monocytes, suggests that chronic activation of immune responses may underlie long-term bone loss. It is important to point out that bone loss in HIV-infected patients on ART is also polymorphic and that even within a defined cohort there are subjects who are resistant to bone loss and other with extensive bone loss. The factors playing into this are likely complex and multifactorial but the extent of T cell reconstitution, number of starting, and ending T cells, and other immune cells, may well play into the eventual outcome.

Author Manuscript

Eight week old mice were used for adoptive transfer, a time at which the long bones are still growing and accreting bone mass. As a consequence, T cell adoptive transfer leads to a significant delta between sham and experimental groups as a consequence of both bone loss and a failure to accrete new bone mass. These femoral data may provide clues as to the effects of T cell reconstitution on bone modeling in children initiating ART. However, as vertebral BMD peaks earlier (around 8 to 12 weeks) in this strain, reconstituted animals show a significant loss of BMD that may more closely represent bone remodeling in adult humans initiating ART. The TCR $\beta$  KO mouse however is a thymus independent model of T cell deficiency and despite the relatively young age of the mice the T cell reconstitution phase of the study is likely representative of human adults where the thymus is expected to be largely atrophic and unlikely to significantly contribute to T cell restoration. Competition from *de novo* T cell generation through the thymus may significantly alter the dynamic in children and remains to be studied.

Author Manuscript

Since the majority of HIV-infected adults have declining bone mass due to natural aging, interventions to prevent further bone loss are needed in this population. The transient and early increase in bone resorption following ART-initiation<sup>19,52</sup> suggests a potential for short-term anti-resorptive therapy, for which we provide a proof of concept in T cell reconstituted mice. Importantly, zoledronic acid did not impair T cell reconstitution in these immunodeficient mice. Therefore, short-term use of this and related bone protective agents may be safe in HIV-infected patients initiating ART. In fact, zoledronic acid has been used successfully in the treatment of osteoporosis in HIV-infected patients<sup>53,54</sup> and extending treatment pre-emptively to protect against ART-associated bone loss, even in non-osteoporotic patients, may be an important future approach to reducing fracture in this at risk population.

Author Manuscript

Because, immune-reconstitution in mice led to not only cortical, but also dramatic trabecular bone loss, even under conditions where cortical bone loss was not induced, it is important to note that traditional DXA-based bone densitometry measurements in patients significantly underestimate trabecular bone loss and may thus underestimate the extent of total bone loss, and hence fracture risk. This is especially problematic in younger populations where fracture risk does not directly correlate with BMD T-scores<sup>55</sup> leading to a conservative approach to therapy.

Although our animal model may not completely recapitulate the complexity of HIV infection state and the effect of ART in humans, it does offer a unique opportunity to isolate the bone impact of immune reconstitution in a background of immunodeficiency without the plethora of confounding variables that plague clinical studies in human.

Author Manuscript

In conclusion, our data demonstrate a cause-effect relationship between T cell repopulation and/or immune reconstitution and osteoclastic bone loss. These data provide a proof of concept that enhanced bone loss associated with ART initiation may be related, in large part, to immune regeneration and/or reactivation rather than, or in addition to, direct effects of ART on bone cells. In our animal model, short-term anti-resorptive therapy prevented bone loss associated with T cell repopulation and should be explored further in HIV-infected patients starting ART.

## MATERIALS AND METHODS

### Mice

All animal studies were approved by the Emory University Institutional Animal Care and Use Committee (IACUC) and were conducted in accordance with the National Institutes of Health Laboratory Guide for the Care and Use of Laboratory Animals. Mice were housed under specific pathogen-free conditions and were fed gamma-irradiated 5V02 mouse chow (Purina Mills) and autoclaved water ad libitum. The animal facility was kept at 23°C ( $\pm 1^\circ\text{C}$ ) with 50% relative humidity and a 12 hour/12 hour light/dark cycle.

Animals were distributed into experimental groups based on baseline BMD measurements of lumbar spine and femurs in order to minimize variances in total BMD between groups that could bias outcomes in cross sectional studies such as in vitro  $\mu\text{CT}$  and histomorphometry.

### T cell adoptive transfer

$\text{CD3}^+$  T cells were purified from the spleens of 6-8 week old female WT C57BL6 mice. For some studies T cells were harvested from 6-8 week old female  $\text{TNF}\alpha$  KO C57BL6 mice purchased from Jackson Labs (Bar Harbor, ME) or 6-8 week old female RANKL KO mice on the C57BL6 background. RANKL KO mice were obtained from an Emory breeding colony derived from donors originally provided by Dr. Yongwon Choi (University of Pennsylvania)<sup>56,57</sup>. T cells were purified by negative immunomagnetic isolation (Stem Cell Inc.) to 97 % purity (Supplementary Figure1A). All buffers, reagents and materials used in T cell purification were sterile and endotoxin free and T cells were processed under sterile conditions. Unless otherwise stated  $1 \times 10^5$  purified T cells were adoptively transferred by tail vein injection into syngeneic female C57BL6  $\text{TCR}\beta$  KO mice at 8 weeks of age. Sham mice were tail vein injected with vehicle (phosphate buffered saline [PBS]). Where indicated, mice received a single 0.4 mg/kg intraperitoneal (IP) dose of zoledronic acid (Novartis Pharmaceutical Corporation) at the time of T cell adoptive transfer. Some T cell reconstituted  $\text{TCR}\beta$  KO mice were injected IP 3 times per week for 3 months with 3 mg/kg of the pharmacological  $\text{TNF}\alpha$  antagonist Etanercept (Pfizer Inc.). Mice were sacrificed 3 months after adoptive transfer for detailed bone and immuno-phenotyping.

### Bone densitometry

BMD measurements were performed in anesthetized mice at baseline (0) and at 2, 4, 8 and 12 weeks following sham or T cell reconstitution by DXA using a PIXImus 2 bone densitometer (GE Medical Systems) as described<sup>58</sup>. Data are presented as percentage change from baseline for each mouse. Baseline BMD ( $\text{g}/\text{cm}^2$ ) for each mouse in each group are located in Supplementary Tables 1 to 4.

### Micro-computed tomography

$\mu\text{CT}$  was performed in femurs *ex vivo* using a  $\mu\text{CT}40$  scanner that was calibrated weekly with a factory-supplied phantom (Scanco Medical, Bassersdorf, Switzerland) as described<sup>58,59</sup>. For trabecular bone 100 tomographic slices were taken (total area of 600  $\mu\text{m}$ ) at the distal right femoral metaphysis at a voxel size of 6  $\mu\text{m}$  (70 kVp and 114 mA, and 200

ms integration time). Trabecular bone was segmented from the cortical shell, for a total area of 0.6 mm beginning ~0.5 mm from the distal growth plate and projection images reconstructed using the autocontour function for trabecular bone. Cortical bone was quantified at the mid-diaphysis from 100 slices at a voxel size of 6  $\mu\text{m}$ . Representative samples were reconstructed in 3D to generate visual representations of cortical and trabecular structure. Indices and units are standardized per the “Guidelines for assessment of bone microstructure in rodents using micro-computed tomography”<sup>60</sup>.

### Quantitative bone histomorphometry

Bone histomorphometric analysis was performed at the University of Alabama at Birmingham Center for Metabolic Bone Disease– Histomorphometry and Molecular Analysis Core Laboratory, as previously described by us<sup>59,61</sup>. Briefly trichrome-stained plastic-embedded sections of calcein double labeled femora from sham and CD3<sup>+</sup> T cell reconstituted mice were analyzed by an operator blinded as to the nature of the samples. Indices and units are reported per the revised recommendations of the ASBMR Histomorphometry Nomenclature Committee<sup>62</sup>.

### Biochemical indices of bone resorption

CTx, Osteocalcin, total RANKL, OPG and TNF $\alpha$  were quantified in mice serum 12 weeks after T cell transfer using RATlaps (CTx) and Rat-MID (osteocalcin) ELISAs (Immunodiagnostic Systems Inc. Fountain Hills AZ) and ELISAs from R&D Systems for RANKL, OPG and TNF $\alpha$ .

### *In vitro* osteoclastogenesis assays

Whole bone marrow was cultured in  $\alpha$ MEM supplemented with 10% Fetal Bovine Serum (FBS) and treated with rmM-CSF (30  $\mu\text{g}/\text{mL}$ ). After 9 days TRAP<sup>+</sup> multinucleated cells ( 3 nuclei) were quantitated under light microscopy and normalized for size based on number of nuclei.

### Flow cytometry

**Surface staining**—Single cell suspensions of spleens and bone marrow were prepared and surface staining performed on  $1 \times 10^6$  cells per reaction in FACS buffer (PBS containing 1% Fetal Bovine Serum (FBS)) for 30 minutes at 4°C followed by one wash in FACS buffer and fixation in PBS containing 1% paraformaldehyde. All antibodies were purchased from eBioscience Inc. (San Diego, CA), unless otherwise indicated. For direct staining of T cells, we used rat anti-mouse CD4-FITC (clone Gk1.5, 0.25  $\mu\text{g}/\text{test}$ ) and CD8-APC (clone 53-6.7, 0.125  $\mu\text{g}/\text{test}$ ); B cells were stained using cd45R (B220)-FITC (clone RA3-6B2, 0.5  $\mu\text{g}/\text{test}$ ); monocytes/macrophages were stained using CD11b-APC (cloneM1/70, 0.125  $\mu\text{g}/\text{test}$ ) and CD11c-APC (clone N418, 0.25  $\mu\text{g}/\text{test}$ ); myeloid lineage and bone marrow stromal cells were stained using rat anti-mouse CD106 (VCAM-1)-FITC (clone 429, 0.5  $\mu\text{g}/\text{test}$ ), Armenian hamster anti-mouse/rat CD29-APC (clone Hmb1-1, 0.25  $\mu\text{g}/\text{test}$ ) and rat anti-mouse Ly-6A/E (Sca-1)-FITC (clone D7, 0.5  $\mu\text{g}/\text{test}$ ). Rat isotype and fluorochrome matched controls, as well as fluorescence-minus-one (FMO) controls were

used to control for non-specific binding and to set gates (see Supplementary Figures 10 and 11).

Indirect surface staining for RANKL was performed as previously described<sup>33</sup>. Briefly, cells were incubated with human OPG-Fc (R&D Systems) at 1 µg/ml for 30 minutes in FACS buffer, followed by anti-human IgG-Fc-PE at 1 µg/test. To ensure specific detection of RANKL, we included controls stained with anti-human IgG Fc-PE without prior pre-incubation with OPG-Fc, and consistently observed negligible background staining levels < 5% non-specific binding.

**Intracellular staining for TNFα production**—Cells were cultured unstimulated for 4 hours with the protein transport inhibitor Golgistop (BD Biosciences) in 12-well flat-bottomed plates (Costar, Cambridge, MA) at a concentration of  $2.5 \times 10^6$  cells/well in a volume of 2 ml complete medium. The cells were harvested, washed once in FACS buffer, and surface stained for lineage markers in FACS buffer as indicated above. After washing the unbound antibody, cells were fixed and permeabilized using the Cytotfix/Cytoperm kit according to the manufacturer's instructions (BD Biosciences). Spontaneous intracellular TNFα production was quantified by flow cytometry using PE-conjugated monoclonal rat anti-mouse TNFα antibody (clone MP6-XT22, 0.125 µg/test). Isotype control antibody (PE rat IgG1, 0.125 µg/test) (BD Biosciences) was used to control for non-specific binding and as a reference to set gates.

The minimal number of events for BM CD4 or CD8 subset analysis was 1,250 – 2,500 cells. Samples were acquired on an Accuri flow cytometer (BD Immunocytometry Systems) and the data analyzed with Flowjo software version 9.5.3 (Treestar Inc. Ashland, OR).

### Statistical Analysis

Statistical significance was determined using GraphPad Prism 5.0 for Mac (GraphPad Software Inc. La Jolla, CA). Multiple cross sectional comparisons were performed by Kruskal-Wallis 1 way ANOVA with Dunn's Multiple Comparison post hoc test. For simple comparisons between two groups we used the Mann-Whitney test for non-parametric data. Prospective changes over time between two groups were analyzed by 2-Way ANOVA with Bonferroni post-test.  $P < 0.05$  was considered statistically significant.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### ACKNOWLEDGEMENTS

The authors thank Drs. Max Cooper, Jeffrey L. Lennox and Anandi Sheth (Emory University) for critical reading of the manuscript and helpful suggestions. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under Award Number R01AR059364 and by the National Institute on Aging (NIA) under Award Number R01AG040013 to M.N.W. and I.O. M.N.W. is also supported by a grant from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (5I01BX000105) and by NIAMS grant (R01AR056090). M.Z. is also supported by NIAMS grant (R01AR053898). Histology services were performed by the University of Alabama at Birmingham, Center for Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core Laboratory, supported by NIAMS (P30AR46031).

## Abbreviations used

<b>ART</b>	antiretroviral therapy
<b>BM</b>	bone marrow
<b>BMSC</b>	bone marrow stromal cells
<b>BMD</b>	bone mineral density
<b>CTx</b>	C-terminal telopeptide of collagen type I
<b>DXA</b>	dual energy X-ray absorptiometry
<b>μCT</b>	micro-computed tomography
<b>OPG</b>	osteoprotegerin
<b>RANK</b>	receptor activator of NF-κB
<b>RANKL</b>	RANK ligand
<b>TCRβ</b>	T cell receptor beta

## REFERENCES


1. Tebas P, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. *AIDS*. 2000; 14:F63–67. [PubMed: 10770534]
2. Thomas J, Doherty SM. HIV infection--a risk factor for osteoporosis. *J Acquir Immune Defic Syndr*. 2003; 33:281–291. [PubMed: 12843738]
3. Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. *Curr Opin Endocrinol Diabetes Obes*. 2010; 17:523–529. [PubMed: 20844427]
4. Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. *Arch Biochem Biophys*. 2010; 503:66–77. [PubMed: 20682280]
5. Arora S, et al. HIV and bone loss. *Curr Osteoporos Rep*. 2010; 8:219–226. [PubMed: 20830538]
6. Ofotokun I, Weitzmann MN. HIV and bone metabolism. *Discov Med*. 2011; 11:385–393. [PubMed: 21616037]
7. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. *AIDS*. 2006; 20:2165–2174. [PubMed: 17086056]
8. Bonjoch A, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. *AIDS*. 2010; 24:2827–2833. [PubMed: 21045635]
9. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. *AIDS*. 2010; 24:2337–2345. [PubMed: 20683316]
10. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. *J Clin Endocrinol Metab*. 2008; 93:3499–3504. [PubMed: 18593764]
11. Prior J, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. *Osteoporos Int*. 2007; 18:1345–1353. [PubMed: 17665239]
12. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. *Clin Infect Dis*. 2011
13. Womack JA, et al. Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans. *PLoS One*. 2011; 6:e17217. [PubMed: 21359191]
14. Guerri-Fernandez R, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. *J Bone Miner Res*. 2013; 28:1259–1263. [PubMed: 23362011]

15. Prieto-Alhambra D, et al. HIV Infection and Its Association With an Excess Risk of Clinical Fractures: A Nationwide Case-Control Study. *J Acquir Immune Defic Syndr*. 2014; 66:90–95. [PubMed: 24457634]
16. Vikulina T, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. *Proc Natl Acad Sci U S A*. 2010; 107:13848–13853. [PubMed: 20643942]
17. Titanji K, et al. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. *PLoS pathogens*. 2014; 10:e1004497. [PubMed: 25393853]
18. Gazzola L, et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. *Journal of translational medicine*. 2013; 11:51. [PubMed: 23448662]
19. McComsey GA, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. *Clin Infect Dis*. 2010; 51:937–946. [PubMed: 20839968]
20. Yin MT, et al. Short-term bone loss in HIV-infected premenopausal women. *J Acquir Immune Defic Syndr*. 2010; 53:202–208. [PubMed: 19890216]
21. Bolland MJ, Grey A. HIV and Low Bone Density: Responsible Party, or Guilty by Association? *IBMS BoneKEy*. 2011; 8:7–15.
22. Gibellini D, et al. Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. *New Microbiol*. 2010; 33:109–115. [PubMed: 20518272]
23. Grigsby IF, Pham L, Gopalakrishnan R, Mansky LM, Mansky KC. Downregulation of *Gnas*, *Got2* and *Snord32a* following tenofovir exposure of primary osteoclasts. *Biochem Biophys Res Commun*. 2010; 391:1324–1329. [PubMed: 20026012]
24. Grigsby IF, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. *Biochem Biophys Res Commun*. 2010; 394:48–53. [PubMed: 20171173]
25. Wang MW, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. *J Clin Invest*. 2004; 114:206–213. [PubMed: 15254587]
26. Brown TT, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. *J Acquir Immune Defic Syndr*. 2009; 51:554–561. [PubMed: 19512937]
27. Piso RJ, Rothen M, Rothen JP, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. *J Acquir Immune Defic Syndr*. 2011; 56:320–324. [PubMed: 21350365]
28. Tebas P, et al. Initiation of ART is associated with bone loss independent of the specific ART regimen: Results of ACTG A5005s. 14th Conference on Retroviruses and Opportunistic Infections. 2007:837.
29. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. *AIDS*. 2003; 17:1917–1923. [PubMed: 12960824]
30. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. *Nature*. 1999; 402:304–309. [PubMed: 10580503]
31. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. *Crit Rev Oral Biol Med*. 2001; 12:125–135. [PubMed: 11345523]
32. Teng YT. The role of acquired immunity and periodontal disease progression. *Crit Rev Oral Biol Med*. 2003; 14:237–252. [PubMed: 12907693]
33. Eghbali-Fatourehchi G, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. *J Clin Invest*. 2003; 111:1221–1230. [PubMed: 12697741]
34. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. *J Clin Invest*. 2006; 116:1186–1194. [PubMed: 16670759]
35. Parfitt AM, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res*. 1987; 2:595–610. [PubMed: 3455637]
36. Tang Y, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. *Nat Med*. 2009; 15:757–765. [PubMed: 19584867]




37. Grant PM, et al. Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. *Clin Infect Dis.* 2013; 57:1483–1488. [PubMed: 23943825]
38. Cenci S, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. *J Clin Invest.* 2000; 106:1229–1237. [PubMed: 11086024]
39. Lam J, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. *J Clin Invest.* 2000; 106:1481–1488. [PubMed: 11120755]
40. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. *Endocrinology.* 2002; 143:1108–1118. [PubMed: 11861538]
41. Black DM, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med.* 2007; 356:1809–1822. [PubMed: 17476007]
42. Andersson J, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. *Aids.* 1998; 12:F123–129. [PubMed: 9708402]
43. Keating SM, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women. *Aids.* 2011
44. Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. *Antiviral therapy.* 2011; 16:1063–1072. [PubMed: 22024522]
45. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. *Immunity.* 2013; 39:633–645. [PubMed: 24138880]
46. Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. *Curr HIV/AIDS Rep.* 2012; 9:16–25. [PubMed: 22179898]
47. Franco JM, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. *Blood.* 2002; 99:3702–3706. [PubMed: 11986226]
48. Kalayjian RC, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. *J Infect Dis.* 2005; 192:1577–1587. [PubMed: 16206072]
49. Roederer M. Getting to the HAART of T cell dynamics. *Nat Med.* 1998; 4:145–146. [PubMed: 9461179]
50. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. *Annual review of medicine.* 2011; 62:141–155.
51. Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. *Arthritis Res Ther.* 2003; 5:225–234. [PubMed: 12932282]
52. Briot K, et al. Prospective one-year bone loss in treatment-naive HIV+ men and women on single or multiple drug HIV therapies. *Bone.* 2011
53. Bolland MJ, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. *J Clin Endocrinol Metab.* 2007; 92:1283–1288. [PubMed: 17227801]
54. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. *Aids.* 2009; 23:51–57. [PubMed: 19050386]
55. Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. *J Clin Invest.* 1988; 81:1804–1809. [PubMed: 3384952]
56. Kim D, et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. *J Exp Med.* 2000; 192:1467–1478. [PubMed: 11085748]
57. Knoop KA, Butler BR, Kumar N, Newberry RD, Williams IR. Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine. *Am J Pathol.* 2011; 179:1861–1871. [PubMed: 21854748]
58. Li Y, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. *Blood.* 2007; 109:3839–3848. [PubMed: 17202317]

59. Roser-Page S, Vikulina T, Zayzafoon M, Weitzmann MN. CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model. *Arthritis & rheumatology*. 2014; 66:990–999. [PubMed: 24757150]
60. Bouxsein ML, et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res*. 2010; 25:1468–1486. [PubMed: 20533309]
61. Li Y, et al. Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. *J Bone Miner Res*. 2007; 22:646–655. [PubMed: 17266397]
62. Dempster DW, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res*. 2013; 28:2–17. [PubMed: 23197339]



**Figure 1. T cell reconstitution induces bone turnover and loss of BMD and bone structure in TCR $\beta$  KO mice**

BMD (% change from baseline) was quantified by DXA prospectively at baseline, 2, 4, 8 and 12 weeks following T cell ( $1 \times 10^5$  CD3<sup>+</sup> T cells) transplant or vehicle injection (sham) at (A) total body, (B) lumbar spine, (C) femurs and (D) tibias. Data expressed as mean  $\pm$  SEM, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , 2-Way ANOVA with Bonferroni post-test ( $n = 8$  mice per group). At 12 weeks the following cross sectional endpoints were analyzed: (E) micro-computed tomography of representative femoral cortical (upper panels) and trabecular (lower panels) high resolution (6  $\mu\text{m}$ ) 3D reconstructions. White bar represents 500  $\mu\text{m}$ . (F) Histological sections of distal femur from sham and CD3<sup>+</sup> T cell reconstituted mice. Mineralized bone stains blue (red arrows indicate trabeculae in the metaphysis and yellow arrows in the epiphysis). White bar represents 200  $\mu\text{m}$ . Serum ELISAs were used to quantify: (G) CTx, (H) osteocalcin, (I) RANKL, (J) OPG, (K) TNF $\alpha$ . Data points represent individual animals with median (black line),  $n = 8$  mice per group. \* $P < 0.05$ , \*\* $P < 0.01$  or \*\*\* $P < 0.001$  by Mann-Whitney test. (L) *In vitro* osteoclastogenesis assay. TRAP<sup>+</sup> multinucleated (3 nuclei) cells were generated from bone marrow from 4 individual mice per group with 5 wells per mouse averaged per data point. Data representative of 2 independent experiments and presented as individual wells with median (black line). \* $P < 0.05$  by Mann-Whitney test.




**Figure 2. Proportion of immune cells producing RANKL and TNF $\alpha$  following T cell reconstitution**

Expression of RANKL was quantified by flow cytometry in WT control mice and TCR $\beta$  KO mice 1 week following reconstitution with  $1 \times 10^5$  CD3 $^+$  T cells (TCR $\beta$ +T cells) in: (A) BM CD4 $^+$  T cells; spleen CD4 $^+$  T cells; (C) BM CD8 $^+$  T cells and (D) spleen CD8 $^+$  T cells.

Expression of RANKL was further quantified in: (E) total BM B-lineage; (F) BM immature B cells and B cell precursors; (G) mature BM B cells; (H) mature B cells in spleen; (I) osteoblasts; (J) BM stromal cells (BMSC); (K) BM dendritic cells and (L) splenic dendritic cells.


Expression of TNF $\alpha$  was quantified by flow cytometry in WT control mice and TCR $\beta$  KO mice 1 week after reconstitution with T cells (TCR $\beta$ +T cells) in: (M) BM CD4 $^+$  T cells; (N) spleen CD4 $^+$  T cells; (O) BM CD8 $^+$  T cells and (P) spleen CD8 $^+$  T cells.

Expression of TNF $\alpha$  was further quantified in: (Q) total BM B-lineage; (R) BM immature B cells and B cell precursors; (S) mature BM B cells; (T) mature B cells in spleen. Data points represent individual animals with median (black line), n=6 independent mice per group. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001 by Kruskal-Wallis 1-way ANOVA with Dunn's Multiple Comparison post-test for 3 groups or Mann-Whitney for simple comparisons between two groups.




**Figure 3. Reconstitution of TCR $\beta$  KO mice with TNF $\alpha$  KO T cells or RANKL KO T cells blunts cortical but not trabecular bone loss**

T cell adoptive transfer was performed by transplanting  $1 \times 10^5$  WT CD3<sup>+</sup> T cells,  $1 \times 10^5$  TNF $\alpha$  KO CD3<sup>+</sup> T cells or  $1 \times 10^5$  RANKL KO CD3<sup>+</sup> T cells into TCR $\beta$  KO mice. BMD was quantified by DXA at baseline and 12 weeks following T cell transplant at: (A) total body, (B) femurs and (C) lumbar spine. Cross sectional endpoints were analyzed at 12 weeks after transfer for: (D) micro-computed tomography of representative cortical (left panels) and trabecular (right panels) high resolution (6  $\mu$ m) 3D reconstructions of femurs. White bar represents 500  $\mu$ m. Serum ELISAs were used to quantify: (E) CTx, (F) osteocalcin, (G) RANKL, and (H) OPG and (I) TNF $\alpha$ . Data points represent individual animals with median (black line), \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  by Kruskal-Wallis 1-way ANOVA with Dunn's Multiple Comparison post-test (n=12 sham, 11 WT, 8 TNF $\alpha$  KO and 7 RANKL KO mice per group).




**Figure 4. Pharmacological TNF $\alpha$  ablation blunts cortical but not trabecular bone loss caused by T cell reconstitution**

TCR $\beta$  KO mice were treated with Etanercept, a TNF $\alpha$  decoy receptor, after adoptive transfer of  $1 \times 10^5$  WT CD3 $^+$  T cells. BMD (% change from baseline) was quantified by DXA prospectively at baseline, 2, 4, 8 and 12 weeks following T cell (CD3 $^+$  T cells) transplant or vehicle injection (sham) at (A) total body, (B) lumbar spine, (C) femurs and (D) tibias. Data expressed as mean  $\pm$  SEM, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  compared to sham by 2-Way ANOVA with Bonferroni post-test ( $n = 8$  mice per group). Cross sectional endpoints were analyzed at 12 weeks after transplant for: (E) micro-computed tomography. Representative cortical (upper panels) and trabecular (lower panels) high-resolution (6  $\mu$ m) 3D reconstructions of femurs from T cell reconstituted mice, with or without Etanercept at 12 weeks. White bar represents 500  $\mu$ m. Serum ELISAs were used to quantify: (F) CTx, (H) osteocalcin, (G) RANKL, and (I) TNF $\alpha$ . Data points represent individual animals with median (black line), \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  by Kruskal-Wallis 1-way ANOVA with Dunn's Multiple Comparison post-test ( $n = 7$  mice per group).



**Figure 5. Starting T cell number impacts the magnitude of bone loss in trabecular and cortical bone compartments**

T cell adoptive transfer dose response was performed by transplanting (0,  $1 \times 10^3$ ,  $1 \times 10^5$  or  $1 \times 10^7$ ) WT CD3<sup>+</sup> T cells into TCR $\beta$  KO mice. BMD was quantified by DXA at baseline and 12 weeks following T cell transplant at (A) lumbar spine, and (B) femurs. Cross sectional endpoints were analyzed at 12 weeks after transplant for: (C) micro-computed tomography or representative cortical (upper panels) and trabecular (lower panels) high resolution (6  $\mu$ m) 3D reconstructions of femurs from T cell reconstituted mice at 12 weeks. White bar represents 500  $\mu$ m. Serum ELISAs were used to quantify: (D) CTx, (E) osteocalcin, (F) RANKL, (G) OPG, and TNF $\alpha$  (H). Data points represent individual animals with median (black line), \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  compared to control (0 T cells) by Kruskal-Wallis 1-way ANOVA with Dunn's Multiple Comparison post-test (n=8 mice per group).



**Figure 6. Proposed model of ART-induced bone loss**

ART-induced T cell restoration and/or immune reactivation (T cell/antigen presenting cell (APC) activity and/or T cell/humoral immunity) leads to osteoclastogenic cytokine production including RANKL and TNF $\alpha$  by T cells and B cells and TNF $\alpha$  by monocytes. These cytokines of immune origin distort the immuno-skeletal interface impacting the skeletal system as RANKL binds to its receptor RANK on osteoclast precursors causing them to differentiate into pre-osteoclasts that fuse into giant multinucleated mature bone resorbing osteoclasts. The association of TNF $\alpha$  with its receptors on osteoclast lineage cells may further synergize with RANKL signal transduction, thus amplifying osteoclast formation and driving up bone resorption leading to bone loss.



**Table 1**Femoral  $\mu$ CT and Bone Histomorphometry Analysis of T cell Reconstituted Mice.

$\mu$ CT	Sham Median (IQR)	CD3 <sup>+</sup> T cells Median (IQR)	% Change	P
<b>Trabecular Indices</b>				
TV [mm <sup>3</sup> ]:	1.291 (0.149)	1.324 (0.113)	+3.3	0.2345
BV [mm <sup>3</sup> ]:	0.0679 (0.016)	0.0371 (0.008)	-45.4	*0.0006
BV/TV [%]:	5.260 (1.482)	2.875 (0.615)	-45.3	*0.0002
Tb.Th [mm]:	0.0399 (0.0018)	0.0286 (0.0052)	-28.4	*0.0019
Tb. N [/mm]:	3.457 (0.428)	2.875 (0.267)	-16.8	*0.0006
Tb. Sp [mm]:	0.3033 (0.0409)	0.3590 (0.0318)	+18.4	*0.0011
TV. D [mg HA/cm <sup>3</sup> ]	41.56 (19.80)	5.46 (15.66)	-86.9	*0.0002
<b>Cortical Indices</b>				
Ct. Th [mm]:	0.1810 (0.0067)	0.1445 (0.0255)	-20.2	*0.0027
Ct. Ar [mm <sup>2</sup> ]:	0.7379 (0.0838)	0.5983 (0.0967)	-18.9	*0.0047
<b>Histomorphometry</b>				
	Sham Median (IQR)	CD3 <sup>+</sup> T cells Median (IQR)	% Change	P
<b>Osteoblasts &amp; Bone formation</b>				
N.Ob/BS:	17.13 (4.23)	9.29 (10.90)	-45.8	*0.0401
MAR [ $\mu$ m/day]:	1.67 (0.38)	1.38 (0.40)	-17.5	*0.0289
BFR/BS [ $\mu$ m/per day]:	0.76 (0.33)	0.65 (0.40)	-14.4	0.2319
BFR/TV [per day]:	0.0040 (0.0026)	0.0021 (0.0011)	-46.7	*0.0234

**Structural indices:** total volume (TV), trabecular bone volume (BV), bone volume fraction (BV/TV), trabecular thickness (Tb. Th), trabecular separation (Tb. Sp), trabecular number (Tb. N); cortical area (Ct. Ar) and cortical thickness (Ct. Th).

**Histomorphometric indices:** number of osteoblasts per bone surface (N.Ob/BS), mineral apposition rate (MAR) and bone formation rate (BFR) per bone surface (BFR/BS) and per tissue volume (BFR/TV).

All data presented as Median with Interquartile Range (IQR) of N= 8 mice per group. Exact P values from Mann-Whitney tests are presented.

\* P 0.05

**Table 2**Femoral Structural Indices in TCR $\beta$  KO Mice Reconstituted with WT, TNF $\alpha$  KO or RANKL KO T cells

	Sham Median (IQR)	WT T cells Median (IQR)	TNF $\alpha$ KO T cells Median (IQR)	RANKL KO T cells Median (IQR)
<b>Trabecular Indices</b>				
TV [mm <sup>3</sup> ]:	1.263 (0.088)	1.459 (0.307)**	1.277 (0.100)	1.292 (0.068)
TV [ ]	0	+15.5	+1.1	+1.3
BV [mm <sup>3</sup> ]:	0.0628 (0.0176)	0.0373 (0.0273)**	0.0317 (0.0090)**	0.0328 (0.0358)*
BV [ ]	0	-40.7	-49.6	-47.8
BV/TV [%]:	5.065 (1.372)	2.380 (1.730)***	2.385 (0.737)**	2.540 (2.750)*
BV/TV [ ]	0	-53.0	-52.9	-49.9
Tb.Th [mm]:	0.04045 (0.0050)	0.0346 (0.0104)	0.04395 (0.0071) <sup>§</sup>	0.0413 (0.0140)
Tb.Th [ ]	0	-14.5	+8.7	+2.1
Tb.N [/mm]:	3.164 (0.381)	2.597 (0.581)***	2.820 (0.377)	2.726 (0.462)
Tb.N [ ]	0	-17.9	-10.9	-13.8
Tb. Sp [mm]:	0.3162 (0.0427)	0.3990 (0.0821)***	0.3709 (0.0494)**	0.3687 (0.0526)
Tb. Sp [ ]	0	+26.2	+17.3	+16.6
TV. D [mg HA/cm <sup>3</sup> ]:	50.97 (15.82)	2.665 (23.76)***	15.85 (23.36)*	26.69 (43.46)
TV. D [ ]	0	-94.8	-63.0	-47.6
<b>Cortical Indices</b>				
Ct. Th [mm]:	0.1785 (0.0068)	0.1300 (0.0350)***	0.1645 (0.0322)	0.1810 (0.0190) <sup>§§§</sup>
Ct. Th [ ]	0	-27.2	-7.8	+1.4
Ct. Ar [mm <sup>2</sup> ]:	0.7483 (0.0700)	0.5685 (0.3177)***	0.6612 (0.1158)	0.7298 (0.0679) <sup>§§</sup>
Ct. Ar [ ]	0	-24.0	-11.6	-2.5

Structural indices: total volume (TV), trabecular bone volume (BV), bone volume fraction (BV/TV), trabecular thickness (Tb. Th), trabecular separation (Tb. Sp), trabecular number (Tb. N); cortical area (Ct. Ar) and cortical thickness (Ct. Th). Data presented as Median with Interquartile Range (IQR) of N=12 Sham, 11 WT T cells, 8 TNF KO T cells and 7 RANKL KO T cells mice/group,

\* p<0.05.

\*\* p<0.01;

\*\*\* p<0.001 vs. Sham;

§§ p<0.01;

§§§ p<0.001 vs. WT T cells by 1 way ANOVA with Kruskal Wallis post-test. ( =% Change from Sham)

**Table 3**Femoral  $\mu$ CT Analysis of T cell Reconstituted Mice Treated with Etanercept.

<b>Trabecular Indices</b>	<b>Sham Median (IQR)</b>	<b>CD<sup>3</sup> T cells Median (IQR)</b>	<b>% Change of Sham</b>	<b>CD<sup>3</sup> T cells + Etanercept Median (IQR)</b>	<b>% Change of Sham</b>
TV [mm <sup>3</sup> ]:	1.402 (0.150)	1.447 (0.145)*	+3.2	1.388 (0.205)	-1.0
BV [mm <sup>3</sup> ]:	0.0496 (0.041)	0.0318 (0.0167)*	-35.9	0.0364 (0.0177)	-26.6
BV/TV [%]:	3.540 (3.310)	2.200 (1.120)*	-37.9	2.590 (1.220)	-26.8
Tb.Th [mm]:	0.0428 (0.007)	0.0325 (0.006)*	-24.1	0.0379 (0.017)	-11.5
Tb.N [/mm]:	2.489 (0.529)	2.506 (0.307)	+0.7	2.634 (0.488)	+5.8
Tb. Sp [mm]:	0.3982 (0.094)	0.3977 (0.0488)	-0.1	0.3854 (0.0846)	-3.2
TV. D [mg HA/cm <sup>3</sup> ]:	14.51 (16.81)	2.424 (5.00)*	-83.3	11.06 (22.21)	-23.7
<b>Cortical Indices</b>					
Ct. Th [mm]:	0.1650 (0.0170)	0.1280 (0.0240)**	-22.4	0.1580 (0.0210)	-4.2
Ct. Ar [mm]:	0.7795 (0.1099)	0.5875 (0.0888)***	-24.6	0.7332 (0.0541)	-5.9

**Structural indices:** total volume (TV), trabecular bone volume (BV), bone volume fraction (BV/TV), trabecular thickness (Tb. Th), trabecular separation (Tb. Sp), trabecular number (Tb. N); cortical area (Ct. Ar) and cortical thickness (Ct. Th). Data presented as Median with Interquartile Range (IQR) of N=7 mice/group,

\* p<0.05.

\*\* p<0.01;

\*\*\* p<0.001 vs Sham by 1 way ANOVA with Kruskal Wallis post-test.

**Table 4**Femoral Structural Indices in TCR $\beta$  KO Mice Reconstituted with Different Numbers of T cells

<b>Trabecular Indices</b>	<b>0 T cells Median (IQR)</b>	<b>10<sup>3</sup> T cells Median (IQR)</b>	<b>10<sup>5</sup> T cells Median (IQR)</b>	<b>10<sup>7</sup> T cells Median (IQR)</b>
TV [mm <sup>3</sup> ]:	1.291 (0.149)	1.235 (0.123)	1.324 (0.113)	1.281 (0.101)
TV [ ]	0	-4.3	+3.3	-0.8
BV [mm <sup>3</sup> ]:	0.0679 (0.016)	0.0577 (0.0142)	0.0371 (0.008)**	0.0359 (0.0165)**
BV [ ]	0	-15.0	-45.4	-47.2
BV/TV [%]:	5.260 (1.482)	4.555 (1.105)	2.875 (0.615)**	2.775 (1.050)**
BV/TV [ ]	0	-13.4	-45.3	-47.2
Tb.Th [mm]:	0.0399 (0.0018)	0.0361 (0.0092)	0.0286 (0.0052)**	0.0358 (0.0049)
Tb.Th [ ]	0	-9.5	-28.4	-10.3
Tb.N [/mm]:	3.457 (0.428)	3.391 (0.301)	2.875 (0.267)**	3.081 (0.320)
Tb.N [ ]	0	-0.6	-16.8	-10.9
Tb. Sp [mm]:	0.3033 (0.0409)	0.3014 (0.0414)	0.3590 (0.0318)**	0.3339 (0.0308)
Tb. Sp [ ]	0	-0.6	18.4	10.1
TV. D [mg HA/cm <sup>3</sup> ]:	41.56 (19.80)	36.32 (15.5)	5.46 (15.66)***	12.17 (21.59)*
TV.D [ ]	0	-12.6	-86.9	-70.7
<b>Cortical Indices</b>				
Ct. Th [mm]:	0.1810 (0.0067)	0.1820 (0.0095)	0.1445 (0.0255)**	0.1730 (0.0100)
Ct. Th [ ]	0	+0.6	-20.2	-4.4
Ct. Ar [mm <sup>2</sup> ]:	0.7379 (0.0838)	0.7336 (0.0614)	0.5983 (0.0967)**	0.7192 (0.0468)
Ct. Ar [ ]	0	-0.6	-18.9	-2.5

Structural indices: total volume (TV), trabecular bone volume (BV), bone volume fraction (BV/TV), trabecular thickness (Tb. Th), trabecular separation (Tb. Sp), trabecular number (Tb. N); cortical area (Ct. Ar) and cortical thickness (Ct. Th). Data presented as Median with Interquartile Range (IQR) of N=8 mice/group,

\* p<0.05.

\*\* p<0.01;

\*\*\* p<0.001 vs. 0 T cells by 1 way ANOVA with Kruskal Wallis post-test.